Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice
- 1 September 2009
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7 (9), 1517-1522
- https://doi.org/10.1111/j.1538-7836.2009.03532.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparisonHaemophilia, 2007
- Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surfaceJournal of Thrombosis and Haemostasis, 2007
- A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitorsJournal of Thrombosis and Haemostasis, 2006
- Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic reviewCritical Care Medicine, 2005
- The use of recombinant factor VIIa in the treatment of bleeding disordersBlood, 2004
- A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®)Journal of Thrombosis and Haemostasis, 2003
- The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasisDisease-a-Month, 2003
- Rational design of coagulation factor VIIa variants with substantially increased intrinsic activityProceedings of the National Academy of Sciences, 2001
- Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with InhibitorsThrombosis and Haemostasis, 1998
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997